The only story that crossed both halves of your roster
A crypto author and a longevity author covered the same raise this week — the first subject in six weeks to appear on both islands of your roster at once.
Your ten authors behave like two separate publications that happen to share a subscriber. Five cover markets, five cover the body, and in a normal week nothing they write about overlaps. This week one subject did: the funding of longevity trials outside pharma, arrived at from opposite directions — one reading it as capital formation, the other as the only way a trial he cares about gets run.
Share of the week by author.
Capital formation for science is the one real crypto use case left.
If pharma will not run the trial, someone has to fund it.
Arrived under two labels — “VitaDAO’s raise” and “Funding trials outside pharma” — merged as the same referent.
Spot-ETF staking approval
33%4 authors · 3 wk · 4 positions extracted
Leaning with the thesis — 2 of 4 authors, with @udiWertheimer on the other side and 1 reporting without a position.
Approval is mechanically straightforward once in-kind redemption clears.
This is the biggest structural bid of the cycle.
Staking inside a wrapper concentrates validator power; approval is bad for Bitcoin's case.
Mechanically it works, but the yield passthrough is smaller than people think.
Four of your five crypto voices are now on the same trade — and none of them agree on the size of it
The section's centre of gravity moved to Washington. The stablecoin markup, a solo beat two weeks ago, now carries three authors; ETF staking carries four. But the numeric claims underneath them are nowhere near as convergent as the coverage: stated odds of approval run from 55% to 85%, and on MicroStrategy the roster's fair-value estimates differ by a factor of two. The one subject where everybody sounds certain — BIP-110 — is also the one where only two authors are looking.
Tight. hasufl 85% · cobie 80% · 0xngmi 60% · udiWertheimer 55%
Approval is mechanically straightforward once in-kind redemption clears.
This is the biggest structural bid of the cycle.
Staking inside a wrapper concentrates validator power; approval is bad for Bitcoin's case.
Mechanically it works, but the yield passthrough is smaller than people think.
Tight. biancoresearch 35% · hasufl 65% · cobie 50%
The bill entrenches incumbent banks and taxes the float.
Imperfect, but it legalises the only product with real demand.
Anything that ends the offshore banking circus is good.
Pin position is direction × conviction: hedged positions sit closer to the centre. The band is the spread of the section’s positions on that subject — a wide band is a real argument, a tight one is a chorus.
Spot-ETF staking approval
Stablecoin bill markup
MSTR treasury strategy critique
Cites primary material on 2 of 4 subjects — the sourced version of what others assert.
Cites primary material on 1 of 2 subjects — the sourced version of what others assert.
Cites primary material on 1 of 2 subjects — the sourced version of what others assert.
Covers 3 shared subjects and broke none of them.
Covers 4 shared subjects and broke none of them.
@hasufl on the stablecoin markup. It is the only primary-source reading of the subject three of your authors now cover, which makes the other two coverages redundant rather than confirming.
The protocol arguments hold, but the doses do not: five weeks of agreement hiding a 60% spread
Nothing here turned over this week — four of five authors are on rapamycin for the sixth consecutive week, which in this half of your roster is the normal state. The movement is in the numbers rather than the positions: weekly dose recommendations range from 5mg to 8mg with one author declining to dose at all, and the cardio argument has quietly inverted, with zone-2 hours now spanning 2.5 to 4.5 depending on whom you read. One genuinely new subject landed on Monday.
A 8× spread. bryan_johnson 8mg · basedbiohacker 6mg · PeterAttiaMD 5mg · hubermanlab 0mg
Weekly dosing is not supported for humans; the interval matters more than the dose.
Pulsed weekly with a washout is the only protocol with a coherent mechanism.
Six weeks on, five off — the n=1 markers are unambiguous.
The mouse data does not transfer cleanly; I would not dose yet.
Tight. drmarkhyman 4.5h · hubermanlab 3h · PeterAttiaMD 2.5h
VO2max carries more hazard-ratio signal than any other modifiable metric.
Order matters less than total volume for most people.
Zone 2 is being dismissed on a misreading of the mitochondrial literature.
Pin position is direction × conviction: hedged positions sit closer to the centre. The band is the spread of the section’s positions on that subject — a wide band is a real argument, a tight one is a chorus.
Rapamycin dosing intervals
Zone 2 vs VO2max priority
CGMs for non-diabetics
Cites primary material on 2 of 3 subjects — the sourced version of what others assert.
Cites primary material on 1 of 2 subjects — the sourced version of what others assert.
Cites primary material on 1 of 2 subjects — the sourced version of what others assert.
Cites primary material on 1 of 3 subjects — the sourced version of what others assert.
Covers 2 shared subjects and broke none of them.
@PeterAttiaMD on apnea underdiagnosis. Nobody else in your roster has touched it in two weeks of coverage, and it is the only item this week that could change what you do rather than what you think.